Small reduction in lung function with Tx de-escalation in COPD

September 15, 2018

(HealthDay)—A de-escalation from triple therapy to indacaterol/glycopyrronium may lead to a small reduction in lung function in non-frequently exacerbating patients with chronic obstructive pulmonary disease (COPD) but no difference in exacerbations, according to a study published in the Aug. 1 issue of the American Journal of Respiratory and Critical Care Medicine.

Kenneth R. Chapman, M.D., from the University of Toronto, and colleagues conducted a 26-week randomized trial to examine the direct change from long-term triple therapy (tiotropium, salmeterol, fluticasone propionate) to indacaterol/glycopyrronium or continuation of triple therapy in non-frequently exacerbating patients with moderate-to-severe COPD. A total of 527 and 526 patients were randomized to indacaterol/glycopyrronium and triple therapy, respectively.

The researchers found that there was a reduction in trough forced expiratory volume in one second of −26 ml (95 percent confidence interval, −53 to 1 ml) with inhaled corticosteroids withdrawal, with confidence intervals exceeding the non-inferiority margin of −50 ml. Between treatments, there was no difference in the annualized rate of moderate or severe COPD exacerbations (rate ratio, 1.08; 95 percent confidence interval, 0.83 to 1.4). Lung function loss was greater and exacerbation risk higher for patients with ≥300 blood eosinophils/µl at baseline. The two groups had similar adverse events.

"The higher exacerbation risk in patients with ≥300 blood eosinophils/µl suggests that these patients are likely to benefit from ," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Novartis Pharma, which funded the study.

Explore further: ATS: Indacaterol-glycopyrronium cuts COPD exacerbations

More information: Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

ATS: Indacaterol-glycopyrronium cuts COPD exacerbations

May 16, 2016
(HealthDay)—For patients with a history of chronic obstructive pulmonary disease (COPD) exacerbations, indacaterol-glycopyrronium is more effective for prevention of exacerbations than salmeterol-fluticasone, according ...

Once-daily triple-Tx improves lung function, HRQoL in COPD

August 22, 2017
(HealthDay)—For patients with chronic obstructive pulmonary disease (COPD), once-daily single-inhaler triple therapy is better for lung function and health-related quality of life than inhaled corticosteroid (ICS)/long-acting ...

Triple therapy no benefit for COPD exacerbations

April 26, 2016
(HealthDay)—The addition of tiotropium to long-acting β2-agonists (LABA) and/or inhaled corticosteroids (ICS) does not reduce chronic obstructive pulmonary disease (COPD) exacerbations compared to LABA/ICS alone, according ...

Minor added benefit of indacaterol/glycopyrronium in COPD

February 19, 2014
The drug combination indacaterol/glycopyrronium (trade name: Ultibro Breezhaler, Xoterna Breezhaler) has been approved since September 2013 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit ...

Worse health status with shorter telomere length in COPD

September 13, 2018
(HealthDay)—Patients with chronic obstructive pulmonary disease (COPD) with shorter telomere length have worse health status, according to a study published in the August issue of CHEST.

Increased risk of MI, ischemic stroke after COPD exacerbation

June 19, 2018
(HealthDay)—For adults with chronic obstructive pulmonary disease (COPD), acute exacerbations are associated with increased risk of myocardial infarction and ischemic stroke, according to a study published online May 3 ...

Recommended for you

New treatment significantly reduces cardiovascular events when combined with statins

November 12, 2018
Statins are the most commonly used treatment for cardiovascular disease. Despite reducing certain risk factors, if triglyceride levels remain high with use of statins, there is still a significant risk for heart attack, stroke ...

New strategy discovered toward possible prevention of cancers tied to mono, the 'kissing disease'

November 12, 2018
Researchers from the University of Minnesota, the Howard Hughes Medical Institute, and the University of Toronto have discovered a possible path forward in preventing the development of cancers tied to two viruses, including ...

Kawasaki disease: One disease, multiple triggers

November 12, 2018
Researchers at University of California San Diego School of Medicine, Scripps Institution of Oceanography, and international collaborators have evidence that Kawasaki Disease (KD) does not have a single cause. By studying ...

Combination therapy promising against blindness-causing bacterial keratitis

November 12, 2018
Multidrug-resistant bacterial infections of the cornea are a leading cause of blindness and cannot be effectively managed with current ophthalmic antibiotics. A team of investigators has now devised a combination therapy ...

Study: How vitamin D and fish oil affect risk of heart attack, stroke and cancer

November 12, 2018
For years, it's remained an open question: What effects do dietary supplements such as high doses of vitamin D or omega-3 fatty acids derived from fish oil have on the risk of diseases such as heart attack, stroke and cancer? ...

Hepatitis C treatment can be shortened in 50 percent of patients, study finds

November 12, 2018
Hepatitis C drugs cure more than 90 percent of patients, but can cost more than $50,000 per patient.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.